Sessa Capital’s Agilon Health AGL Stock Holding History

Sessa Capital’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-23,995	Closed	-$2.36M	–	29
2024 Q3	$2.36M	Hold	23,995	–	–	0.09%	26
2024 Q2	$3.92M	Hold	23,995	–	–	0.12%	25
2024 Q1	$3.66M	Hold	23,995	–	–	0.09%	26
2023 Q4	$7.53M	Buy	+23,995	New	+$8.68M	0.25%	18

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sessa Capital's AGL Position: Q4 2024 in Review

Sessa Capital sold out of Agilon Health (AGL) in Q4 2024, closing a stake of 23,995 shares — an estimated $2.36M sold.

Sessa Capital first reported a position in AGL in Q4 2023 and held it in 4 quarters. The position peaked at $7.53M in Q4 2023. 184 funds tracked by Wall St. Rank hold AGL as of Q4 2024.

Sessa Capital reported no remaining Agilon Health position as of Q4 2024 after selling out during the quarter.
Sessa Capital sold 23,995 Agilon Health shares in Q4 2024, an estimated $2.36M.
Sessa Capital first reported a position in Agilon Health in Q4 2023 and held it in 4 quarters.
Sessa Capital's Agilon Health position peaked at $7.53M in Q4 2023.
184 funds tracked by Wall St. Rank held Agilon Health as of Q4 2024.

Based on Sessa Capital's 13F filing for Q4 2024, filed 14 Feb 2025.